Following the full FDA approval of the Pfizer-Biotech vaccine, many are awaiting the full approval of the other Covid-19 vaccines currently operating under Emergency Use Authorization.
The Pfizer vaccine remains the most popular vaccine in the US with a margin of 347 million doses given so far, compared to Moderna’s 314 million. The Janssen Johnson and Johnson vaccine trails behind, but still holds a significant foothold at 20 million doses given.
In December of 2020, Pfizer was granted Emergency use Authorization (EUA) followed closely by Moderna just one week later. The Janssen vaccine was granted EUA more recently, on February 27 2021. This was later amended in April 23 to include information about a rare but serious blood clot found in a few people who received the vaccine.
Until last week, all Covid-19 vaccines in the US have been granted only EUA status by the FDA. It’s important to note that EUA Approval still only comes after rigorous testing and approval standards.
This month, Moderna and Pfizer have both been approved for EUA use as a third “booster” dose in some immunocompromised people.
While the timeline for full FDA Approval of Moderna and Janssen vaccines is still unknown, leading clinical experts look for Moderna to follow closely behind Pfizer’s approval. Moderna officials announced their rolling submission of data to the FDA from their current studies of the vaccine, and this occurred just one month after Pfizer’s submission to the FDA. In theory, full approval of Moderna should be within reach over the next several months at the latest.
Johnson & Johnson has not yet submitted their application for full FDA approval of the The Janssen vaccine, but has announced intent to do so before the end of the year.
Want to Learn More?
In addition to keeping you up to date on all things clinical trials, we also act as a digital CRO with a specific focus on patient recruitment and retention. We believe that patient recruitment and study startup (especially study design and study material) are heavily intertwined. After all, study design can make or break clinical trials, and the patient-perspective should be considered when designing studies to ensure that patient targets are met not only on time, but also on budget.
For Citruslabs, patient recruitment starts with study design and ends with trial completion. We recruit patients through our network of health apps, which enables you to connect with thousands of patients in real time. The best part: these patients are already educated and prepared for the clinical trial process.